Loughborough University
Leicestershire, UK
LE11 3TU
+44 (0)1509 263171
Loughborough University

Loughborough University Institutional Repository

Please use this identifier to cite or link to this item: https://dspace.lboro.ac.uk/2134/4239

Title: Manufacture of a human mesenchymal stem cell population using an automated cell culture platform
Authors: Thomas, Robert James
Chandra, Amit
Liu, Yang
Hourd, Paul C.
Conway, Paul P.
Williams, David J.
Keywords: Cell culture automation
Regenerative medicine
Human mesenchymal stem cells
Commercialisation
Manufacture
Issue Date: 2007
Publisher: © Springer
Citation: THOMAS, R.J. ... et al, 2007. Manufacture of a human mesenchymal stem cell population using an automated cell culture platform. Cytotechnology, 55 (1), pp. 31-39
Abstract: Tissue engineering and regenerative medicine are rapidly developing fields that use cells or cell based constructs as therapeutic products for a wide range of clinical applications. Efforts to commercialise these therapies are driving a need for capable, scaleable, manufacturing technologies to ensure therapies are able to meet regulatory requirements and are economically viable at industrial scale production. We report the first automated expansion of a human bone marrow derived mesenchymal stem cell population (hMSCs) using a fully automated cell culture platform. Differences in cell population growth profile, attributed to key methodological differences, were observed between the automated protocol and a benchmark manual protocol. However, qualitatively similar cell output, assessed by cell morphology and the expression of typical hMSC markers, was obtained from both systems. Furthermore, the critical importance of minor process variation, e.g. the effect of cell seeding density on characteristics such as population growth kinetics and cell phenotype, was observed irrespective of protocol type. This work highlights the importance of careful process design in therapeutic cell manufacture and demonstrates the potential of automated culture for future optimisation and scale up studies required for the translation of regenerative medicine products from the laboratory to the clinic.
Description: This article was published in the journal, Cytotechnology [© Springer] and the original publication is available at www.springerlink.com
Version: Accepted for publication
DOI: 10.1007/s10616-007-9091-2
URI: https://dspace.lboro.ac.uk/2134/4239
ISSN: 0920-9069
1573-0778
Appears in Collections:Published Articles (Mechanical and Manufacturing Engineering)

Files associated with this item:

File Description SizeFormat
CYTO134_revised_2.pdf1.09 MBAdobe PDFView/Open

 

SFX Query

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.